Activates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose.
Reference facts
- Also known as
- GlucaGen, Baqsimi, Gvoke
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Activates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose.
- Targets
- GCGR
- Indications under research or approved
- Severe Hypoglycemia, Diagnostic adjunct in radiology
- Regulatory status (reference entry)
- FDA-approved (multiple formulations)
- Half-life
- ~3–6 minutes
- Sequence
- HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
- Sequence notes
- 29-residue counter-regulatory peptide hormone secreted by pancreatic alpha cells.
- Molecular weight (Da)
- 3485
- PDB accession
- 1GCN
- Originator / sponsor
- Eli Lilly, Novo Nordisk, Xeris
- First reported
- 1923
Primary References
Explore research articles about Glucagon
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.